Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
July 16, 2014

Illumina Buys Myraqa, Continuing Sequencing Push into Clinic

  • Illumina said today it acquired Myraqa, a consulting firm specializing in companion diagnostics and other IVDs, for an undisclosed price.

    The deal is intended to strengthen Illumina’s in-house capabilities to expand genomic technology into clinical settings and prepare for its next growth phase, the sequencing giant said.

    Myraqa—which is led by founder and CEO Mya Thomae—was founded in 1998, and is based in Redwood Shores, CA. Myraqa offers expertise in regulatory, quality, clinical, biostatistics and development, focusing on regulatory strategy and application support, including PMAs, pre-submissions, IDEs, 510(k)s, de novo 510(k)s, and EU technical files.

    Myraqa employees will continue to report to Thomae, who will become Illumina’s vp of regulatory affairs, reporting to Illumina CMO Rick Klausner, M.D.

    “With Myraqa, Illumina will continue to pave the way for the use of genomic technology, including next-generation sequencing, in regulated markets while also driving standards for use in the clinic. Mya will lead Illumina's regulatory strategy and execution, providing us with a world-class regulatory organization and is part of our commitment to making Illumina a pre-eminent clinical company,” Dr. Klausner said in a statement. “We expect Mya and her team to complete existing programs and to continue to work with selected third-parties on sequencing-based projects.”

    Illumina said the financial impact of its Myraqa acquisition, which was not quantified in the announcement, was contemplated when the company released its revised 2014 financial guidance released on April 22.

    The company raised its revenue increase projections above a range disclosed in January, going from between 15% to 17%, to between 21% and 23% this year after finishing 2013 with $1.4 billion in revenue. Illumina also raised its non-GAAP earnings per fully diluted share guidance to between $2.10 and $2.15, from between $2.00 and $2.06.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: [email protected] An error has occurred. Please contact Customer Service at [email protected]
  • You’re all set! Thank you for subscribing to GEN Highlights.